Cara Therapeutics (NASDAQ:CARA) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a report released on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

NASDAQ:CARA opened at $0.34 on Wednesday. Cara Therapeutics has a 12 month low of $0.24 and a 12 month high of $1.31. The firm has a market capitalization of $18.70 million, a PE ratio of -0.17 and a beta of 0.68. The business’s fifty day moving average price is $0.29 and its 200 day moving average price is $0.40.

Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings data on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. The business had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $1.26 million. As a group, equities analysts anticipate that Cara Therapeutics will post -1.24 EPS for the current year.

Institutional Trading of Cara Therapeutics

An institutional investor recently raised its position in Cara Therapeutics stock. Disciplined Growth Investors Inc. MN increased its stake in shares of Cara Therapeutics, Inc. (NASDAQ:CARA) by 6.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,935,718 shares of the biopharmaceutical company’s stock after acquiring an additional 120,660 shares during the quarter. Disciplined Growth Investors Inc. MN owned about 3.54% of Cara Therapeutics worth $499,000 at the end of the most recent quarter. 44.66% of the stock is owned by institutional investors and hedge funds.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.